TABLE 3.
Quantitative evaluation of the different steps of the microarray procedure for the detection of clinical serum samples from Crimean–Congo haemorrhagic fever virus (CCHFV) outbreaks
| Sample | RNA (PFU/mL)a | cDNA (PFU/mL)a | WTA (PFU/mL)a | Call rateb (%) | BLASTN (Homologous Strain) | Divergencec versus homologous strain (%) |
|---|---|---|---|---|---|---|
| Nigeria (supernatant) | 5.9 × 105 | 8.5 × 104 | 1.0 × 1010 | 99.6 | IbAr10200 | 0.2 |
| Mauritania (supernatant) | 8.1 × 106 | 1.8 × 105 | 2.8 × 1012 | 98.0 | ArD39554 | 1.9 |
| Turkey (supernatant) | 6.2 × 106 | 1.5 × 105 | 1.4 × 1011 | 62.9 | Turkey200310849/Kelkit06 | 10.7 |
| China (supernatant) | 9.1 × 105 | 2.2 × 106 | 5.0 × 108 | 30.9 | – | 13.7 |
| Turkey 090137 (serum) | 1.2 × 103 | 2.6 × 103 | 5.6 × 107 | 45.7 | Eurasia | 10.15 |
| Turkey 090139 (serum) | 7.6 × 101 | 2.4 × 101 | 9.9 × 105 | 33.5 | – | 10 |
| Kosovo 422 (serum) | 1.2 × 101 | 2.4 × 100 | 6.1 × 105 | 39.0 | Eurasia | ND |
| Kosovo 423 (serum) | 2.3 × 100 | 1.9 × 100 | 3.5 × 104 | 22.9 | – | 9.2 |
| Kosovo 426 (serum) | 1.1 × 102 | 1.4 × 101 | 8.1 × 104 | ND | ND | 9.8 |
| Kosovo 427 (serum) | 1.8 × 103 | 1.3 × 103 | 1.9 × 106 | 70.8 | Turkey200310849/Kelkit06 | 9.8 |
| Kosovo 429 (serum) | 2.6 × 103 | 7.0 × 102 | 2.8 × 105 | 29.2 | Eurasia | 9.7 |
| Iran 397 (serum) | 7.0 × 102 | 8.5 × 102 | 2.5 × 107 | 23.5 | – | 14.1 |
| Iran 402 (serum) | 3.2 × 104 | 1.8 × 103 | 3.9 × 108 | 26.2 | – | 14.7 |
| Iran 406 (serum) | 1.8 × 104 | 2.9 × 103 | 3.6 × 108 | 24.0 | – | 14.5 |
| Iran 407 (serum) | 4.0 × 104 | 3.2 × 103 | 5.0 × 108 | 28.4 | – | 14.7 |
| Iran 409 (serum) | 4.7 × 103 | 1.9 × 103 | 8.9 × 106 | 21.5 | – | 14.7 |
a
Specific viral genetic material evaluated by quantitative PCR, expressed in equivalent PFU/mL.
b
Call rate for the detection of the strain/isolate on the microarray.
c
Percentage of divergence (531 base pairs region in the polymerase gene) against the sequence tiled on the microarray.
No BLASTN confirmation. ND not done.